Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.49 |
| ▸ | HTR2B | P41595 | 6/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 8/20 | 0.40 |
| ▸ | CD74 | P04233 | 2/20 | 0.39 |
| ▸ | CTSS | P25774 | 2/20 | 0.39 |
| ▸ | SRD5A1 | P18405 | 4/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4716706 | 0.84 | NOTUM (0.56) | HTR2CHTR2BNOTUMHTR2ACTSS | |
| SCHEMBL24895470 | 0.83 | SLC6A2 (0.37) | HTR2CHTR2BHTR2A | |
| SCHEMBL4713862 | 0.81 | NOTUM (0.62) | HTR2CHTR2BNOTUMHTR2ASRD5A1 | |
| SCHEMBL5768740 | 0.80 | HTR2C (0.48) | HTR2CHTR2BNOTUMHTR2A | |
| SCHEMBL3379474 | 0.78 | HTR2C (0.47) | HTR2CHTR2BNOTUM | |
| Hydrochloric Acid SCHEMBL3380183 | 0.77 | HTR2C (0.46) | HTR2CHTR2BNOTUM | |
| SCHEMBL4713768 | 0.77 | MEN1 (0.45) | — | |
| SCHEMBL5547354 | 0.73 | HTR2C (0.44) | HTR2CHTR2BNOTUMHTR2ASRD5A1 | |
| SCHEMBL4717237 | 0.73 | HTR2C (0.47) | HTR2CHTR2BNOTUMHTR2ACD74 | |
| Hydrochloric Acid SCHEMBL8863969 | 0.72 | OPRM1 (0.51) | HTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1315490-B1 | A METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARM INC (US) | 2008-11-12 | — | — | EP | disclosed |
| US-20070117785-A1 | Substituted pyrazoles and methods of treatment with substituted pyrazoles | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-24 | — | — | US | disclosed |
| EP-1309593-B1 | SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARM INC (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050245576-A1 | Substituted pyrazoles | BUTLER CHRISTOPHER R | 2005-11-03 | — | — | US | disclosed |
| US-6953793-B2 | Substituted pyrazoles | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-10-11 | — | — | US | disclosed |
| US-20050101587-A9 | Method for treating allergies using substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICALS, INC. | 2005-05-12 | — | — | US | disclosed |
| US-6583155-B2 | Administering 2-(1-(3-(5-Acetyl-3-(4-chloro-phenyl)-4,5,6,7-tetrahydro-pyrazolo-(4,3 -c)pyridin-1-yl)-2-hydroxy-propyl)-piperidin-4-ylamino)-benzonitrile for inhibiting cathepsins; for treating atopic diseases | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-06-24 | — | — | US | disclosed |
| EP-1315490-A2 | A METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-06-04 | — | — | EP | disclosed |
| EP-1309593-A2 | SUBSTITUTED PYRAZOLES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20030078419-A1 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-04-24 | — | — | US | disclosed |
| US-20020115656-A1 | Method for treating allergies using substituted pyrazoles | BUTLER CHRISTOPHER R (US) | 2002-08-22 | — | — | US | disclosed |
| US-20020055497-A1 | Method for treating allergies using substituted pyrazoles | BUTLER CHRISTOPHER R (US) | 2002-05-09 | — | — | US | disclosed |
| WO-2002020011-A2 | A METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-2002014315-A2 | SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245576-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSV | HTR2C 3881/4885HTR2B 3568/4885NOTUM 1380/4885 |
| US-20030078419-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSV | HTR2C 3881/4885HTR2B 3568/4885NOTUM 1380/4885 |
| US-20020115656-A1 | Method for treating allergies using substituted pyrazoles | TSLP, IL33, HRH2 | HTR2C 970/4885HTR2B 904/4885NOTUM 539/4885 |
| US-20050101587-A9 | Method for treating allergies using substituted pyrazoles | TSLP, IL33, HRH2 | HTR2C 970/4885HTR2B 904/4885NOTUM 539/4885 |
| US-20020055497-A1 | Method for treating allergies using substituted pyrazoles | TSLP, IL33, HRH2 | HTR2C 970/4885HTR2B 904/4885NOTUM 539/4885 |
| US-20070117785-A1 | Substituted pyrazoles and methods of treatment with substituted pyrazoles | CTSS, CMA1, CTSZ | HTR2C 2413/4885HTR2B 2134/4885NOTUM 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.